LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)

Recruiting

• Conditions: Lung Cancer

• Registration Number: NCT04228237
• Lead Sponsor: Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.

Brief Summary

Long-term non-interventional monitoring of diagnostics and treatment patterns in newly diagnosed patients in selected pneumology centers in Czech republic.

Detailed Description

Diagnosis, treatment and care of patients with bronchogenic carcinoma (BCA) is, as with most other oncological diseases, a complex multidisciplinary process. Due to the lack of information on the speed and success of the initial diagnosis, the use of the necessary laboratory techniques, and the individual therapeutic steps leading to cure or medical failure, the Czech Pneumological and Phtizeology Society (CPPS) decided to carry out long-term non-interventional monitoring of newly diagnosed patients.

This monitoring is non-interventional, so the usual diagnostic and therapeutic procedures will be used according to the decision of the physician. All patients with bronchogenic carcinoma diagnosed from June 1, 2018 will be enrolled with up to 60 months of follow-up.

Study Timeline

• Study Start: 2018-06-01
• Study First Submitted: 2019-10-31
• Study First Submitted QC: 2020-01-10
• Study First Posted: 2020-01-14
• Status Verified: 2022-03
• Last Update Submitted: 2022-03-07
• Last Update Posted: 2022-03-09
• Primary Completion: 2025-05-31
• Study Completion: 2025-05-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2300

Inclusion Criteria

• clinical diagnosis of lung cancer (C34 in MKN classification)

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to treatment discontinuation (TTD)	any treatment during 60 months of follow-up	time from starting a medication until treatment discontinuation or death
Progression-free survival (PFS)	any treatment during 60 months of follow-up	Time from randomization until disease progression or death
Overall survival (OS)	60 months of follow-up	Time from randomization until death from any cause

Secondary Outcome Measures

Name	Time	Method
Time to next treatment (TTNT)	60 months of follow-up	Time from end of primary treatment to institution of next therapy

Trial Locations

Locations (7)

University hospital Brno; 🇨🇿 Brno, Czechia

University hospital Hradec Kralove; 🇨🇿 Hradec Kralove, Czechia

University hospital Motol; 🇨🇿 Praha 5, Czechia

University hospital Olomouc; 🇨🇿 Olomouc, Czechia

University hospital Plzen; 🇨🇿 Plzen, Czechia

University hospital Bulovka; 🇨🇿 Praha 8, Česká Republika, Czechia

University Thomayer hospital; 🇨🇿 Prague, Czechia